AR101290A1 - Inhibidores de aldosterona sintasa - Google Patents
Inhibidores de aldosterona sintasaInfo
- Publication number
- AR101290A1 AR101290A1 ARP150102340A ARP150102340A AR101290A1 AR 101290 A1 AR101290 A1 AR 101290A1 AR P150102340 A ARP150102340 A AR P150102340A AR P150102340 A ARP150102340 A AR P150102340A AR 101290 A1 AR101290 A1 AR 101290A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- compounds
- heteroaryl
- sintasa
- Prior art date
Links
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 title 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 title 1
- 229960002478 aldosterone Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
Composiciones farmacéuticas que comprenden estos compuestos, a métodos para usar estos compuestos en el tratamiento de varias enfermedades y trastornos, a procesos para preparar estos compuestos y a intermediarios útiles en estos procesos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) en donde: Cy es un sistema de anillos monocíclicos o bicíclicos seleccionados de C₃₋₁₀cicloalquilo, heterociclilo, arilo y heteroarilo, en donde cada grupo C₃₋₁₀cicloalquilo, heterociclilo, arilo y heteroarilo se sustituye, independientemente y de manera opcional, con 1, 2 ó 3 grupos sustituyentes seleccionados de halógeno, -C₁₋₃-alquilo, -OC₁₋₃-alquilo, -CF₃, ciano, oxo, -N(C₁₋₃-alquilo)₂, -NH(C₁₋₃-alquilo), -NHCOC₁₋₃-alquilo, -C(O)C₁₋₃-alquilo, -C(O)OC₁₋₃-alquilo, hidroxi-C₁₋₃-alquilo o heteroarilo; y R¹ y R² se seleccionan independientemente de H, C₁₋₃-alquilo, hidroxi-C₁₋₃-alquilo, -CH₂NHC(O)OC₁₋₄-alquilo, -CH₂OC(O)C₁₋₄-alquilo, -C(O)OC₁₋₄-alquilo, -C(O)H, -COOH, -C(O)NHC₁₋₄-alquilo y C(O)N(C₁₋₄-alquilo)₂; o R¹ y R² tomados juntos forman un C₃₋₆-cicloalquilo o C₃₋₆-heterociclilo; o una sal de aquel.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028556P | 2014-07-24 | 2014-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101290A1 true AR101290A1 (es) | 2016-12-07 |
Family
ID=53761616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102340A AR101290A1 (es) | 2014-07-24 | 2015-07-23 | Inhibidores de aldosterona sintasa |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9334285B2 (es) |
| EP (1) | EP3172212B1 (es) |
| JP (1) | JP6250862B2 (es) |
| KR (1) | KR102378648B1 (es) |
| CN (1) | CN106488921B (es) |
| AP (1) | AP2016009616A0 (es) |
| AR (1) | AR101290A1 (es) |
| AU (1) | AU2015292632B2 (es) |
| BR (1) | BR112017000584B1 (es) |
| CA (1) | CA2956118C (es) |
| CL (1) | CL2017000040A1 (es) |
| CO (1) | CO2017000443A2 (es) |
| CY (1) | CY1121063T1 (es) |
| DK (1) | DK3172212T3 (es) |
| EA (1) | EA031105B1 (es) |
| ES (1) | ES2684050T3 (es) |
| HR (1) | HRP20181441T1 (es) |
| HU (1) | HUE039981T2 (es) |
| IL (1) | IL249665B (es) |
| LT (1) | LT3172212T (es) |
| MX (1) | MX368093B (es) |
| MY (1) | MY191352A (es) |
| NZ (1) | NZ727188A (es) |
| PE (1) | PE20170294A1 (es) |
| PH (1) | PH12017500089B1 (es) |
| PL (1) | PL3172212T3 (es) |
| PT (1) | PT3172212T (es) |
| RS (1) | RS57570B1 (es) |
| SG (1) | SG11201700595RA (es) |
| SI (1) | SI3172212T1 (es) |
| TW (1) | TWI600658B (es) |
| UA (1) | UA118801C2 (es) |
| UY (1) | UY36228A (es) |
| WO (1) | WO2016014736A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108587B (zh) * | 2014-10-15 | 2020-05-22 | 勃林格殷格翰国际有限公司 | 醛固酮合成酶抑制剂 |
| US9890171B2 (en) * | 2014-12-02 | 2018-02-13 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| US10858342B2 (en) | 2016-06-28 | 2020-12-08 | Boehringer Ingelheim International Gmbh | Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases |
| SG10201610038SA (en) * | 2016-07-29 | 2017-12-28 | Apple Inc | Systems and methods for management of asymmetrical multi-tapped battery packs |
| JP7530384B2 (ja) | 2019-05-01 | 2024-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート |
| TW202339719A (zh) | 2021-12-14 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療慢性腎臟病之醛固酮合成酶抑制劑 |
| US20250057829A1 (en) | 2023-08-18 | 2025-02-20 | Boehringer Ingelheim International Gmbh | Inhibitors of trpc6 for treating focal segmental glomerulosclerosis |
| WO2025174790A1 (en) | 2024-02-14 | 2025-08-21 | Boehringer Ingelheim International Gmbh | Solid forms of an aldosterone synthase inhibitor |
| WO2025190858A1 (en) | 2024-03-12 | 2025-09-18 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitor for treating heart failure |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100703068B1 (ko) * | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| BRPI0709678A2 (pt) * | 2006-03-29 | 2011-07-19 | Novartis Ag | compostos orgánicos |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TWI577671B (zh) * | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
| US8912341B2 (en) * | 2013-01-16 | 2014-12-16 | Northwestern University | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones |
-
2015
- 2015-07-23 HU HUE15744459A patent/HUE039981T2/hu unknown
- 2015-07-23 MY MYPI2016002216A patent/MY191352A/en unknown
- 2015-07-23 UA UAA201701595A patent/UA118801C2/uk unknown
- 2015-07-23 NZ NZ727188A patent/NZ727188A/en unknown
- 2015-07-23 AR ARP150102340A patent/AR101290A1/es active IP Right Grant
- 2015-07-23 US US14/806,706 patent/US9334285B2/en active Active
- 2015-07-23 PT PT15744459T patent/PT3172212T/pt unknown
- 2015-07-23 PL PL15744459T patent/PL3172212T3/pl unknown
- 2015-07-23 LT LTEP15744459.7T patent/LT3172212T/lt unknown
- 2015-07-23 AP AP2016009616A patent/AP2016009616A0/en unknown
- 2015-07-23 MX MX2017000929A patent/MX368093B/es active IP Right Grant
- 2015-07-23 RS RS20180970A patent/RS57570B1/sr unknown
- 2015-07-23 EA EA201790253A patent/EA031105B1/ru not_active IP Right Cessation
- 2015-07-23 AU AU2015292632A patent/AU2015292632B2/en active Active
- 2015-07-23 JP JP2017503920A patent/JP6250862B2/ja active Active
- 2015-07-23 WO PCT/US2015/041648 patent/WO2016014736A1/en not_active Ceased
- 2015-07-23 SG SG11201700595RA patent/SG11201700595RA/en unknown
- 2015-07-23 PE PE2017000086A patent/PE20170294A1/es unknown
- 2015-07-23 BR BR112017000584-0A patent/BR112017000584B1/pt active IP Right Grant
- 2015-07-23 CA CA2956118A patent/CA2956118C/en active Active
- 2015-07-23 DK DK15744459.7T patent/DK3172212T3/en active
- 2015-07-23 TW TW104123931A patent/TWI600658B/zh active
- 2015-07-23 KR KR1020177005181A patent/KR102378648B1/ko active Active
- 2015-07-23 HR HRP20181441TT patent/HRP20181441T1/hr unknown
- 2015-07-23 SI SI201530354T patent/SI3172212T1/sl unknown
- 2015-07-23 EP EP15744459.7A patent/EP3172212B1/en active Active
- 2015-07-23 CN CN201580036596.3A patent/CN106488921B/zh active Active
- 2015-07-23 ES ES15744459.7T patent/ES2684050T3/es active Active
- 2015-07-24 UY UY0001036228A patent/UY36228A/es active IP Right Grant
-
2016
- 2016-12-20 IL IL249665A patent/IL249665B/en active IP Right Grant
-
2017
- 2017-01-06 CL CL2017000040A patent/CL2017000040A1/es unknown
- 2017-01-13 PH PH12017500089A patent/PH12017500089B1/en unknown
- 2017-01-19 CO CONC2017/0000443A patent/CO2017000443A2/es unknown
-
2018
- 2018-09-04 CY CY181100920T patent/CY1121063T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101290A1 (es) | Inhibidores de aldosterona sintasa | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| MX2019001581A (es) | Inhibidores de ssao de aminopirimidina. | |
| EP4067347C0 (en) | HETEROCYCLIC CBP/EP300 INHIBITORS FOR THE TREATMENT OF CANCER | |
| CL2017001566A1 (es) | Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales. | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| EP3263132C0 (en) | COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6 | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| AR093705A1 (es) | Depsipeptido y sus usos | |
| DOP2017000178A (es) | Inhibidores selectivos de bace1 | |
| EA201691512A1 (ru) | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 | |
| MA40848A (fr) | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EP3359521C0 (en) | NEW COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |